Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths.
Patients with USC share many genomic and clinical characteristics with patients who has
serous ovarian cancer. The objective of this study is to evaluate the efficacy of maintenance
Niraparib regimen in patients with advanced or platinum sensitive recurrent uterine serous
carcinoma. Additionally, the investigators aim to further describe the safety of this
regimen. The investigators hypothesize that Niraparib maintenance will be a well-tolerated
treatment and show significant response in patients with uterine serous carcinoma.